Table 2. Contraindications, warnings, and precautions for the SGLT2 inhibitors^1,2.

	Canagliflozin	Dapagliflozin
Contraindications
Severe renal impairment	X	X
End-stage renal disease or dialysis	X	X
Hypersensitivity to the agent	X	X
Warnings and precautions
Volume depletion/hypotension	X	X
Impairment in renal function	X	X
Hyperkalemia	X
Hypoglycemia	X	X
Genital mycotic infections	X	X
Hypersensitivity reactions	X
LDL-C	X	X
Bladder cancer		X
Macrovascular outcomes not studied	X	X
Special populations
Renal impairment	Reduce dose if GFR 45 to < 60 mL/min/1.73 m2 Avoid if GFR is < 45 mL/min/1.73 m2	Avoid if GFR < 60 mL/min/1.73 m2
Hepatic impairment	No unique precautions in mild to moderate impairment Not studied in severe impairment; therefore, use is not recommended	No unique precautions in mild to moderate impairment Not studied in severe impairment; therefore, risk versus benefit should be considered
Elderly	Increased risk of volume depletion	Increased risk of volume depletion and
Pediatric	Safety and efficacy not established	Safety and efficacy not established
Pregnancy	Category C; avoid use	Category C; avoid use
Lactation	Avoid use	Avoid use

Note: GFR = glomerular filtration rate; LDL-C = low-density lipoprotein cholesterol.